# Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects

> **NCT04229303** · PHASE1 · COMPLETED · sponsor: **Zambon SpA** · enrollment: 58 (actual)

## Conditions studied

- Allergic Bronchopulmonary Aspergillosis

## Interventions

- **DRUG:** Voriconazole inhaled
- **DRUG:** oral voriconazole

## Key facts

- **NCT ID:** NCT04229303
- **Lead sponsor:** Zambon SpA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-11
- **Primary completion:** 2020-08-31
- **Final completion:** 2020-08-31
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2021-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04229303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04229303, "Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04229303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*